SLC22A1 and hepatocellular carcinoma: A retrospective analysis of 39 HCC patients, treated with sorafenib, revealed a correlation of decreased OCT1 level at the plasma membrane, rather than total OCT1 levels, with better outcome in sorafenib-treated patients [73].